These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25683616)

  • 1. Systemic glucocorticoids: important issues and practical guidelines for the dermatologist.
    Dodiuk-Gad RP; Ish-Shalom S; Shear NH
    Int J Dermatol; 2015 Jun; 54(6):723-9. PubMed ID: 25683616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers in the management of glucocorticoid-induced osteoporosis.
    Guzman-Clark JR; Fang MA; Sehl ME; Traylor L; Hahn TJ
    Arthritis Rheum; 2007 Feb; 57(1):140-6. PubMed ID: 17266078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid-induced bone loss in dermatologic patients: an update.
    Summey BT; Yosipovitch G
    Arch Dermatol; 2006 Jan; 142(1):82-90. PubMed ID: 16415391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
    Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Suzuki Y; Sato S
    Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid-induced osteoporosis.
    Saag KG
    Endocrinol Metab Clin North Am; 2003 Mar; 32(1):135-57, vii. PubMed ID: 12699296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Assessment of the treatment of glucocorticoid-induced osteoporosis].
    Asano S; Suzuki A
    Clin Calcium; 2013 Mar; 23(3):401-8. PubMed ID: 23445894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.
    De Nijs RN
    Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid-induced osteoporosis: an update on effects and management.
    Buehring B; Viswanathan R; Binkley N; Busse W
    J Allergy Clin Immunol; 2013 Nov; 132(5):1019-30. PubMed ID: 24176682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
    Yosipovitch G; Hoon TS; Leok GC
    Arch Dermatol; 2001 Apr; 137(4):477-81. PubMed ID: 11295929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and treatment of systemic glucocorticoid side effects.
    Moghadam-Kia S; Werth VP
    Int J Dermatol; 2010 Mar; 49(3):239-48. PubMed ID: 20465658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid-induced osteoporosis in dermatologic practice: a review.
    Khan YK; Kalaaji AN; Clarke BL
    J Drugs Dermatol; 2008 Nov; 7(11):1053-9. PubMed ID: 19110736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone safety of low-dose glucocorticoids in rheumatic diseases.
    Saag KG
    Ann N Y Acad Sci; 2014 May; 1318():55-64. PubMed ID: 24815076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
    Soen S
    Nihon Rinsho; 2011 Jul; 69(7):1310-4. PubMed ID: 21774377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disconnect between better quality of glucocorticoid-induced osteoporosis preventive care and better outcomes: a population-based cohort study.
    Majumdar SR; Lix LM; Morin SN; Yogendran M; Metge CJ; Leslie WD
    J Rheumatol; 2013 Oct; 40(10):1736-41. PubMed ID: 23818715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions.
    Bultink IE; Baden M; Lems WF
    Expert Opin Pharmacother; 2013 Feb; 14(2):185-97. PubMed ID: 23317448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of risk of glucocorticoid-induced osteoporosis due to systemic administration in general practice in Denmark.
    Nielsen BR; Jørgensen NR; Schwarz P
    Eur J Gen Pract; 2007; 13(3):168-71. PubMed ID: 17853181
    [No Abstract]   [Full Text] [Related]  

  • 18. Recommendations for the registration of agents to be used in the prevention and treatment of glucocorticoid-induced osteoporosis: updated recommendations from the Group for the Respect of Ethics and Excellence in Science.
    Abadie EC; Devogealer JP; Ringe JD; Ethgen DJ; Bouvenot GM; Kreutz G; Laslop A; Orloff JJ; Vanderauwera PM; Delmas PD; Dere WH; Branco J; Altman RD; Avouac BP; Menkes CJ; Vanhaelst L; Mitlak BH; Tsouderos Y; Reginster JY
    Semin Arthritis Rheum; 2005 Aug; 35(1):1-4. PubMed ID: 16084217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current topics over updating guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
    Suzuki Y
    Clin Calcium; 2014 Mar; 24(3):417-24. PubMed ID: 24576939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city.
    Caballero-Uribe CV; Acosta-Velez JG; Hernandez-Ruiz EA; Andrade Rodado FM; Peñuela-Epalza M
    J Clin Rheumatol; 2008 Jun; 14(3):153-5. PubMed ID: 18525434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.